Business Context and Reporting Period
Company: Church & Dwight Co., Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended October 1, 2004.
Key Event: On May 28, 2004, the Company completed the acquisition of the remaining 50% interest in Armkel, LLC, consolidating its results into the financial statements from May 29, 2004. This transaction significantly altered the Company's segment structure and financial profile.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Oct 1, 2004 | 3 Months Ended Sept 26, 2003 | 9 Months Ended Oct 1, 2004 | 9 Months Ended Sept 26, 2003 |
|---|---|---|---|---|
| Net Sales | $420,310 | $265,566 | $1,057,086 | $770,127 |
| Gross Profit | $160,589 | $80,542 | $376,827 | $233,949 |
| Gross Margin % | 38.2% | 30.3% | 35.6% | 30.4% |
| Net Income | $27,401 | $19,522 | $76,880 | $65,094 |
| Diluted EPS | $0.42 | $0.31 | $1.19 | $1.03 |
| Operating Cash Flow (9mo) | $143,963 (2004) vs $78,858 (2003) | |||
| Total Debt | $901,834 (Oct 1, 2004) vs $397,046 (Dec 31, 2003) | |||
| Cash & Equivalents | $145,440 (Oct 1, 2004) vs $75,634 (Dec 31, 2003) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 58.2% in the quarter and 37.3% year-to-date. The primary driver was the consolidation of Armkel sales ($114.8M in Q3; $158.3M YTD) and the Unilever oral care business acquired in late 2003.
- Margin Expansion: Gross margin improved significantly (38.2% vs 30.3% in Q3) due to the higher-margin profile of acquired Armkel and Unilever products, partially offset by a $6.2M inventory step-up charge related to the Armkel acquisition.
- Debt Increase: Total debt more than doubled to $901.8M. This reflects the assumption of Armkel's $225M Senior Subordinated Notes, $136M in bank debt, and new Term Loans ($540M total) used to fund the acquisition.
- Interest Expense: Interest expense rose sharply to $17.8M in Q3 (from $4.8M) and $29.3M YTD (from $14.7M). This includes $4.9M in interest expense related to the settlement of the Carter-Wallace shareholder appraisal suit.
- Equity Earnings: Equity in earnings of affiliates decreased significantly ($1.1M in Q3 vs $5.2M prior year) because the Company now consolidates Armkel rather than accounting for it under the equity method.
Outlook, Risks, and Unusual Items
- Unusual Items:
- Medpointe Settlement: The Company settled legal actions regarding the Carter-Wallace merger, agreeing to pay $8.1M. $4.9M was recorded as interest expense in Q3, and $3.2M was applied to goodwill.
- Debt Extinguishment: A $7.995M loss on early extinguishment of debt was recorded in the nine-month period due to the write-off of deferred financing costs upon refinancing.
- Impairment: A $1.5M plant impairment charge was recorded in Q2 2004.
- Guidance & Outlook: Management expects to significantly increase marketing spending in Q4 to support new product launches (e.g., Arm & Hammer Enamel Care, Trojan Warming Sensations) and acquired oral care brands. The Company plans to invest $30M in Del Laboratories, Inc. in Q4.
- Risks & Contingencies:
- Regulatory: Potential FDA restrictions on nonoxynol-9 (N-9) in condoms could impact financial results.
- Commodity Costs: Rising energy and raw material prices are being managed through cost reduction and selective price increases.
- Legal: Pending litigation with Fleming Companies, Inc. regarding bankruptcy preference payments ($4.2M claim).
- Accounting Changes: New rules (EITF 04-8) regarding contingently convertible debt will have an estimated $0.02 dilutive effect on EPS starting in reporting periods ending after December 15, 2004.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the new Credit Agreement leverage ratio (Total Debt to Adjusted EBITDA). The ratio was 3.14x as of Oct 1, 2004, well below the 4.25x maximum.
- Armkel Integration: Confirm the final purchase price allocation and valuation of Armkel tradenames, which are currently at book value pending appraisal.
- Del Labs Investment: Monitor the closing of the $30M investment in Del Laboratories and the associated option rights for the Orajel brand.
- EPS Dilution: Review the impact of the new EITF 04-8 rule on diluted EPS calculations in the upcoming 2004 annual report.
- Working Capital: Assess the sustainability of the $144M operating cash flow given the significant increase in debt service obligations.